<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE- dexamethasone, neomycin sulfate and polymyxin b sulfate ointment </strong><br>Paddock Laboratories, LLC<br></p></div>
<h1>
<span class="Bold">Neomycin and </span><span class="Bold">Polymyxin</span><span class="Bold"> B Sulfates and Dexamethasone Ophthalmic Ointment USP</span><br><span class="Bold">STERILE</span><br><span class="Bold">Rx Only</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_adf3d307-988f-4b29-be18-314bd72d7da7"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment USP is a multiple dose anti-infective steroid combination in a sterile ointment for topical application. The active ingredient dexamethasone, is represented by the following structural formula:</p>
<div class="Figure">
<a name="id-128403905"></a><img alt="Structural Formula Image 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c8ae4afe-4f06-4441-9c5b-52f485f8f2f5&amp;name=c8ae4afe-4f06-4441-9c5b-52f485f8f2f5-01.jpg">
</div>
<p>C<span class="Sub">22</span>H<span class="Sub">29</span>FO<span class="Sub">5</span> Mol. Wt. 392.47</p>
<p>Chemical Name: Pregna-1,4-diene-3,20-dione, 9-fluoro-11, 17,21-trihydroxy-16-methyl-, (11ß, 16α)-.</p>
<p>Neomycin Sulfate is the sulfate salt of neomycin B and C which are produced by the growth of <span class="Italics">Streptomyces </span><span class="Italics">fradiae</span><span class="Italics"></span>Waksman (Fam. Streptomycetaceae). It has a potency equivalent to not less than 600 micrograms of neomycin base per milligram, calculated on an anhydrous basis. The structural formula are:</p>
<div class="Figure">
<a name="id1976183202"></a><img alt="Structural Formula Image 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c8ae4afe-4f06-4441-9c5b-52f485f8f2f5&amp;name=c8ae4afe-4f06-4441-9c5b-52f485f8f2f5-02.jpg">
</div>
<p>Polymyxin B Sulfate is the sulfate salt of polymyxin B<span class="Sub">1</span> and B<span class="Sub">2</span> which are produced by the growth of <span class="Italics">Bacillus </span><span class="Italics">polymyxa</span><span class="Italics"></span>(Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per milligram, calculated on an anhydrous basis. The structural formula are:</p>
<div class="Figure">
<a name="id807902700"></a><img alt="Structural Formula Image 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c8ae4afe-4f06-4441-9c5b-52f485f8f2f5&amp;name=c8ae4afe-4f06-4441-9c5b-52f485f8f2f5-03.jpg">
</div>
<p>Each gram of ointment contains: ACTIVES: Dexamethasone 1 mg (0.1%), Neomycin Sulfate equivalent to Neomycin 3.5 mg base, Polymyxin B Sulfate 10,000 units in a base containing INACTIVES: White Petrolatum and Mineral Oil.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_b4046115-09a0-49de-9ddb-80ac3d8d9111"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">Corticoids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticoids may inhibit the body's defense mechanism against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.  When a decision to administer both a corticoid and an antimicrobial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered, plus assured compatibility of ingredients when both types of drugs are in the same formulation and, particularly, that the correct volume of drug is delivered and retained. The relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_9d1406ee-04e4-4d00-b95f-19916fb0f7ee"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or risk of bacterial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> exists.</p>
<p>Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitises</span> is accepted to obtain a diminution in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. They are also indicated in chronic <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">anterior uveitis</span> and corneal injury from chemical, radiation or <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">thermal burns</span>; or penetration of foreign bodies.</p>
<p>The use of a combination drug with an anti-infective component is indicated where the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.</p>
<p>The particular anti-infective drugs in this product is active against the following common bacterial eye pathogens:  <span class="Italics">Staphylococcus </span><span class="Italics">aureus</span><span class="Italics">, Escherichia coli, </span><span class="Italics">Haemophilus</span><span class="Italics"></span><span class="Italics">influenzae</span><span class="Italics">, </span><span class="Italics">Klebsiella</span><span class="Italics">/</span><span class="Italics">Enterobacter</span><span class="Italics"></span>species, <span class="Italics">Niesseria</span><span class="Italics"></span>species, and <span class="Italics">Pseudomonas </span><span class="Italics">aeruginosa</span>.</p>
<p>This product does not provide adequate coverage against: <span class="Italics">Serratia</span><span class="Italics"></span><span class="Italics">marcescens</span><span class="Italics"></span>and Streptococci, including <span class="Italics">Streptococcus </span><span class="Italics">pneumoniae</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_75c9caa7-dbaf-4ea7-87e7-0f54c7872701"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and many other viral diseases of the cornea and conjunctiva.  <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">Mycobacterial infection</span> of the eye.  Fungal diseases of ocular structures.  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to a component of the medication.  (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to the antibiotic component occurs at a higher rate than for the other components.)</p>
<p>The use of these combinations is always contraindicated after uncomplicated removal of a corneal foreign body.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID_41998bd2-f33c-47db-aa4e-9b47627e0fcb"></a><a name="section-5"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">NOT FOR INJECTION. Do not touch tube tip to any surface, as this may contaminate the contents.  Prolonged use may result in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, with damage to the optic nerve, defects in visual acuity and fields of vision, and <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. In acute purulent conditions of the eye, steroids may mask <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or enhance existing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If these products are used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients.</p>
<p>Products containing neomycin sulfate may cause cutaneous sensitization. Employment of steroid medication in the treatment of herpes simplex requires great caution.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_65c220ea-6609-4f1d-90d6-dfb8c8e5627c"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS:</h1>
<p class="First">The initial prescription and renewal of the medication order beyond 8 g should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, flourescein staining. The possibility of persistent <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the cornea should be considered after prolonged steroid dosing. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_1b195bd3-f288-42ca-8749-140bbada3e31"></a><a name="section-7"></a><p></p>
<h1>PREGNANCY:</h1>
<div class="Section">
<a name="ID_6e65190f-3552-4666-8f44-080c92478e4b"></a><a name="section-7.1"></a><p></p>
<h2>Pregnancy Category C:</h2>
<p class="First">Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose.</p>
<p>In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>. In the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc.  There are no adequate or well-controlled studies in pregnant women. Neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_efd10660-ba77-48b0-aa87-7d4a08457e70"></a><a name="section-8"></a><p></p>
<h1>NURSING MOTHERS:</h1>
<p class="First">Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_8c3dbdd9-f846-4188-a227-fcad76c624e1"></a><a name="section-9"></a><p></p>
<h1>PEDIATRIC USE:</h1>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_89ec15af-ab0a-48a0-9118-dc22b24267a1"></a><a name="section-10"></a><p></p>
<h1>GERIATRIC USE:</h1>
<p class="First">No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_bd0f6113-66e1-449c-bd5f-8d187259f0a4"></a><a name="section-11"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available.</p>
<p>Reactions occurring most often from the presence of the anti-infective ingredients are allergic sensitizations.  The reactions due to the steroid component are: elevation of intraocular pressure (IOP) with possible development of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and infrequent optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>; <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation; and delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">Secondary Infection</span>: </span>The development of the <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span> has occurred after use of combination containing steroids and antimicrobials. <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infections</span> of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion must be considered in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where steroid treatment has been used. Secondary bacterial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> following suppression of host responses also occurs.</p>
<p><span class="Italics">To report SUSPECTED ADVERSE REACTIONS, contact Perrigo </span><span class="Italics">at 1-866-634-9120,</span><span class="Italics"> or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_54206e8a-aa0b-4233-8105-a8cca293344c"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">Apply a small amount into the conjunctival sac(s) up to three or four times daily.</p>
<p>How to Apply neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment:</p>
<dl>
<dt>1.</dt>
<dd>Tilt your head back.</dd>
<dt>2.</dt>
<dd>Place a finger on your cheek just under your eye and gently pull down until a "V" pocket is formed between your eyeball and your lower lid.</dd>
<dt>3.</dt>
<dd>Place a small amount (about 1/2 inch) of neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment in the "V" pocket. Do not let the tip of the tube touch your eye.</dd>
<dt>4.</dt>
<dd>Look downward before closing your eye.</dd>
</dl>
<p>Not more than 8 g should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in <span class="Bold">PRECAUTIONS </span>above.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_50c7ff1f-5c87-4455-921d-b5651d5b46a5"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment USP is supplied in 3.5 g (1/8 oz) sterile tamper evident tubes with ophthalmic tip.</p>
<p>NDC 0574-<span class="Bold">4160</span>-35</p>
<p>Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].</p>
<p>Manufactured For</p>
<p>Perrigo®</p>
<p>Minneapolis, MN 55427</p>
<p>1R200 RC J1</p>
<p>Rev 12-13 A</p>
<p>Ini 1113 R1113</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_5911665f-5c43-4999-a66b-8a360751d9c3"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Carton</h1>
<p class="First">Rx Only</p>
<p>NDC 0574-<span class="Bold">4160</span>-35</p>
<p>Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment USP</p>
<p>NET WT 3.5 g (1/8 oz)</p>
<p>STERILE</p>
<div class="Figure">
<a name="id-2050138985"></a><img alt="Perrigo Neomycin - Polymyxin Image 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c8ae4afe-4f06-4441-9c5b-52f485f8f2f5&amp;name=c8ae4afe-4f06-4441-9c5b-52f485f8f2f5-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_19f5dfe8-1fe0-4b5f-a992-b744e3c5918b"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Label</h1>
<p class="First">Rx Only</p>
<p>NDC 0574-<span class="Bold">4160</span>-35</p>
<p>Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment USP</p>
<p>NET WT 3.5 g (1/8 oz)</p>
<p>STERILE</p>
<div class="Figure">
<a name="id876282878"></a><img alt="Perrigo Neomycin - Polymyxin Image 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c8ae4afe-4f06-4441-9c5b-52f485f8f2f5&amp;name=c8ae4afe-4f06-4441-9c5b-52f485f8f2f5-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE 		
					</strong><br><span class="contentTableReg">neomycin, polymyxin b sulfates, dexamethasone ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0574-4160</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXAMETHASONE</strong> (DEXAMETHASONE) </td>
<td class="formItem">DEXAMETHASONE</td>
<td class="formItem">1 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>NEOMYCIN SULFATE</strong> (NEOMYCIN) </td>
<td class="formItem">NEOMYCIN</td>
<td class="formItem">3.5 mg  in 1 g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POLYMYXIN B SULFATE</strong> (POLYMYXIN B) </td>
<td class="formItem">POLYMYXIN B</td>
<td class="formItem">10000 [USP'U]  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0574-4160-35</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062938</td>
<td class="formItem">07/03/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Paddock Laboratories, LLC
							(967694121)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c8ae4afe-4f06-4441-9c5b-52f485f8f2f5</div>
<div>Set id: c8ae4afe-4f06-4441-9c5b-52f485f8f2f5</div>
<div>Version: 1</div>
<div>Effective Time: 20140715</div>
</div>
</div> <div class="DistributorName">Paddock Laboratories, LLC</div></p>
</body></html>
